Physician profile
John Garren
NPI 1346738168
$3,381.17
in general payments reported to CMS, 2019-2025
29 companies · $659 in 2025
The $659 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,032 · 2022: $755 · 2023: $477 · 2024: $458 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $596.92 | 2021-2025 | Lifevest |
| Cardiovascular Systems INC. | $462.19 | 2021-2023 | Diamondback Coronary |
| Sanofi-Aventis U.S. LLC | $290.28 | 2021-2024 | |
| Abiomed | $232.79 | 2022-2025 | Impella |
| Merck Sharp & Dohme LLC | $189.15 | 2021-2023 | Verquvo |
| Boston Scientific Corporation | $183.59 | 2022-2025 | Watchman Flx, Avvigo Guidance System, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $180.05 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $157.02 | 2021-2023 | |
| Abbott Laboratories | $151.14 | 2021-2024 | Coroflow, Diamondback Coronary |
| Atricure, INC. | $144.01 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Janssen Pharmaceuticals, INC | $141.90 | 2021-2023 | Xarelto |
| Biotronik INC. | $127.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.86 | 2022-2023 | Jardiance |
| Heartflow, INC. | $56.15 | 2025 | |
| Amgen INC. | $51.62 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $45.43 | 2024 | Arcalyst |
| Novo Nordisk INC | $43.44 | 2025 | Wegovy |
| Pfizer INC. | $41.36 | 2022-2023 | |
| Edwards Lifesciences Corporation | $36.28 | 2024 | Sapien 3 Ultra Resilia |
| Cardinal Health 200 LLC | $23.85 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.14 | 2023 | Opsumit |
| Terumo Medical Corporation | $18.84 | 2025 | Glidewire |
| Medtronic, INC. | $17.23 | 2025 | Corevalve Evolut R |
| Scpharmaceuticals INC. | $16.51 | 2023 | |
| Irhythm Technologies, INC. | $14.43 | 2024 | Zio Xt Patch, Zio Monitor |
| Teleflex LLC | $13.63 | 2022 | |
| Impulse Dynamics (USA) INC. | $13.50 | 2025 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $12.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Garren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.